President Biden orders states to broaden vaccine eligibility by May 1; new data from Novavax, Pfizer point to high vaccine efficacy; Supreme Court will not hear arguments on Medicaid work requirements.
In his first prime-time address as president Thursday night, President Joe Biden instructed states to make all adults 18 years and older eligible for a COVID-19 vaccine by May 1, The Associated Press reports. If Americans continue practicing mitigation efforts like mask wearing and social distancing, Biden said the possibility of returning to a semblance of normal life could be achieved by Independence Day, when Americans may be able to safely gather in small groups. In the address, the president also announced he will deploy 4000 active-duty troops to support vaccination efforts across the country and described the launch of a new website to help individuals find doses once they become eligible.
New data from Novavax Inc show the company’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of SARS-CoV-2, and 86% in doing so against a more contagious variant first detected in the United Kingdom. Results of the late-stage trial conducted in the United Kingdom point to a combined 90% effectiveness rate overall, Reuters reports. In addition, a recent study concluded Pfizer/BioNTech’s approved COVID-19 vaccine is 97% effective against symptomatic COVID-19, according to CBS News. The real-world evidence collected from Israel indicates the vaccine offers more protection than earlier thought. Data also show that prevention against asymptomatic disease reached 94%.
The Supreme Court has called off upcoming arguments on Medicaid work requirements proposed by the Trump administration, according to The Associated Press. The move comes after a request was made by the Biden administration to do so. Although the court was scheduled to hear the issue on March 29, the current administration already decided that work requirements do not support Medicaid’s goal of providing health care to lower-income Americans. The decision marks the fifth time since the 2020 presidential election the court has dismissed or delayed cases it had once agreed to hear.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More